• Gabapentin Reduces Drinking in Patients with AUD 

• No Clearly Effective Treatment for Cannabis Use Disorder Available

• Extended-Release VS Sublingual Buprenorphine Initiation in the ED

• Pharmacy Standing Order and OTC Naloxone and Opioid Fatality

• Rethinking “Success” in Stimulant Use Disorder: Reduced Use vs Total Abstinence

Read Here

• Semalglutide Shows Promise for Alcohol Use Disorder 

• Contingency Management Linked to Reduced Mortality in Stimulant Use Disorder

• Xylazine and Medetomidine Rapidly Spreading in the U.S. Drug Supply

• Psilocybin Shows Efficacy for Cocaine Use Disorder in First Clinical Trial 

• Overdose Prevention Centers and Growing Evidence on Safety and Community Impact

Read Here

• Mirtazapine Showing Promise for Methamphetamine Use Disorder 

• Fentanyl Test Strips Promote Harm Reducing Behaviors

• Inequities Found in Substance Use Disorder Screening and Medication Treatment

• Higher Treatment Retention Rates for Buprenorphine Initiated Via Telehealth

• MOUD Discontinuation Rates During Pregnancy and the Postpartum Period 

Read Here

• GLP-1 Receptor Agonists: A New Frontier In Addiction Treatment

• Psilocybin-Assisted Therapy for Cocaine Use Disorder

• Scaling Contingency Management for Stimulant Use Disorder

• Xylazine and the Evolving Drug Supply

• Safer Opioid Supply and Drug Decriminalization Efforts: Lessons from British Columbia

Read Here

• Navigating the Hard Conversations

• Persistent Stigma in Views of Opioid Use Disorder

• Medications for Alcohol Use Disorder: Structural Gaps and Missed Opportunities

• Comparing Primary Care and Specialty Treatment Outcomes for Buprenorphine

• Practical Perioperative Pain Management for Patients on Buprenorphine

Read Here

• Mindfulness as an Adjunct in Treating Adolescent SUD

• Peer Navigation After Opioid Overdose: Promise, Limits and Importance of Integration

• U.S. Overdose Deaths Are Declining, But the Crisis is Far from Over

• Public Awareness is High, but Stigma Persists

• Psychedelic Retreats and Safety: Wide Variation and Limited Clinical Oversight

Read Here

• Navigating Difficult Conversations About Opioids

• A Turning Point in the Overdose Epidemic: Progress, Causes, and Ongoing Risks

• When Pain and Opioid Use Disorder Overlap in Older Adults

• Persistent Gaps in Access to Medications for Alcohol Use Disorder

• Why the First Opioid Prescription Matters

Read Here

• Novel Benzodiazepines and Emerging Harms: A Scoping Review of Practical Harm Reduction Responses

• Modeling Mortality and Retention: A Decade‑Long Comparison of Methadone and Buprenorphine/Naloxone.

• Enhancing Opioid Withdrawal Management Through Yoga‑Based Autonomic Regulation

• Pharmacotherapy for Alcohol Use Disorder: Proven Tools, Persisting Underuse

• Telehealth Buprenorphine Induction Improves Retention and Reduces Overdose Risk

Read Here

• The Hidden Risks of Health Apps and AI in Addiction Care

• Does Cannabis Use Affect Varenicline Efficacy for Nicotine Vaping Cessation in Youth?

• Enhanced Avoidance Learning in Chronic Opioid Users: Evidence from a Case-Control Study

• Beyond Metabolic Disease: GLP-1RAs in the Management of Addiction

• What It Takes to Stop Opioids: Patient Perspectives on Barriers and Alternatives

Read Here

• Tramadol for Chronic Pain: Modest Benefit, Significant Harm Risk

• Managing In-Hospital Substance Use

• Returning to Practice After Opioid Addiction- A Physician’s Story

• Bridging the Gap: How Technology-Assisted Buprenorphine Transforms OUD Treatment in Rural and Urban Settings

• Why Patients Prefer OUD Care in Primary Care Clinics

Read Here

• New FDA Labeling Rules Target Risks of Long-Term Opioid Use

• Counting the Uncounted: The Public Health Impact of Misclassified OUD

• Less May Be More: Pharmacist-Led Care Reduces Opioids Without Compromising Pain Control

• Bending the Curve, But Not Breaking the Crisis

• Bridging the Gap: Improving Continuity in Extended-Release Naltrexone Treatment for AUD

Read Here

1. Hospital-Based Addiction Consult Services Reduce ED Visits but Fall Short on Long-Term Outcomes for OUD Patients

2. Stigmatized Loss and Childhood Trauma: A Public Health Challenge for Clinicians

3. Family History Matters: Parental Substance Use and Suicide Tied to Elevated Risk of Youth Self-Harm

4. Pharmacist-Led Models for MOUD: Expanding Access Through Community Pharmacies

5. Harm Reduction Attitudes Drive PrEP Prescribing in Rural Primary Care

Read Here

• Shifting Trends, Persistent Gaps: Substance Use and Mental Health in the 2024 NSDUH Report

• New Injectable Buprenorphine Strategy Improves Treatment Access for Vulnerable Populations

• Elevated Overdose Risk Associated with Multiple Prescribers for Concurrent Opioid and Benzodiazepine Therapy

• Evidence-Based Guideline for Treating Substance Use in Adolescents and Young Adults 

• Fentanyl Drives Widespread Shift in Hospital-Based Addiction Treatment 

Read Here

• Cannabis Commercialization: Effects on Tobacco and Vaping Trends

• Soaring ED Visits for Cannabis Hyperemesis Syndrome Among Adolescents

• Telemedicine-Facilitated Hepatitis C Treatment Improves Cure Rates for Patients With OUD 

• Rescue Strategies for Smoking Cessation Treatment Failure

• Impact of Integrated Mental Health and Substance Use Services in Primary Care on Treatment Access

Read Here

• Higher Buprenorphine Initiation Doses May Improve Treatment Retention for OUD in the Fentanyl Era

• Managing Acute Pain with Buprenorphine: Continuity is Key

• Opioid Prescribing: Understanding Patient and Prescription Risks for Misuse

• Unmasking the Power of Stigma: How Public Perceptions Hinder Addiction Recovery

• Overcoming Barriers to MOUD: Lessons from Patient Engagement

Read Here

• Medicaid Unwinding: Impact on Buprenorphine Access for OUD Patients

• Cannabis Use in Older Veterans: Insights for Clinicians

• Oral vs. Injectable Naltrexone for Hospitalized AUD Patients

• Heavy Cannabis Use and Working Memory in Young Adults

• Law Enforcement Seizures Linked to Increased Overdose Risk

Read Here

• A New Standard for Opioid Equivalence: The NIH HEAL Initiative MME Calculator

• Evidence-Informed Strategies for Benzodiazepine Tapering: A Multi-Society Guideline

• Outpatient Buprenorphine Prescribing for Chronic Pain: A Retrospective Analysis of Trends

• Hospital Room Searches and Patient-Directed Discharge: A Retrospective Cohort Study

• Discharge MAUD Initiation Reduces Mortality and Hospital Readmission: A Medicare Part D Study

Read Here

• Pain Management for Pregnant Patients with Opioid Use Disorder: A Consensus Statement

• Comparing Buprenorphine-Naloxone and Buprenorphine for Opioid Use Disorder in Pregnancy

• Drug Overdose Risks Among Healthcare Workers in the U.S.

• The Adolescent Overdose Crisis

• Drug Poisoning and Other Factors Drive Increased Mortality in Young Adults

Read Here

• Integrating Buprenorphine into Community Healthcare: A Key Strategy for Combating the Opioid Crisis

• Trends in Opioid Overdose Deaths

• Challenging the Myths of Suboxone Diversion

• Expanding MOUD Access in Rural Areas: The Role of Telehealth and Hybrid Care Models

• Provider Hesitancy in Prescribing Buprenorphine

Read Here

• The Role of Prescription Psychostimulants in Treating Amphetamine Use Disorder

• Rising Overdose Deaths: The Impact of Fentanyl and Psychostimulant Use

• COVID-19 & Stimulant Use in Youth: Unexpected Trends

• Naltrexone & Bupropion Combo Shows Promise for Methamphetamine Addiction

• Addressing Placebo Response Bias in Psychedelic Research: Comparing Psychedelics and Escitalopram for Depression

Read Here

• Alcohol-Related ED Visits Linked to Increased Mortality Risk in Young Adults

• Understanding the Link Between Alcohol and Pain Relief

• GIP/GLP-1 RAs Linked to Reduced Overdose and Intoxication in OUD/AUD Patients

• The Interplay Between Opioid Misuse, Alcohol Misuse, and Distress in Patients with Chronic Pain

• Management of Alcohol Withdrawal in the Outpatient Setting: A Review of Treatment Options

Read Here

• Increased Likelihood of Precipitated Withdrawal in Patients With Higher BMI’s and/or Elevated Urine Fentanyl Concentrations, When Transitioning From Illicit Fentanyl to Buprenorphine

• Understanding How to Appropriately Utilize Toxicology Testing in Addiction Medicine

• Greater Retention in Treatment Seen With Telemedicine Prescribing of Buprenorphine for Rural Patients

• SGLT2 Inhibitors Causing False Positive Toxicology Tests For Ethanol

• Healthcare Professionals Struggle With Use Disorders in Their Personal Lives as Well- A PCP’s Story About Her Son’s Addiction

Read Here

• Buprenorphine Linked to Lower Overdose Risk After Hospitalization

• Tackling the Root Causes of SUD: A Source Control Framework

• Higher Initial Buprenorphine Doses Linked to Lower Mortality

• Addressing the MOUD Knowledge Gap in Primary Care

• Prescription Opioids and OUD Risk

Read Here